NeuroSense Therapeutics Initiates Regulatory Submission for Early Commercialization of ALS Treatment in Canada

NeuroSense Therapeutics (NASDAQ: NRSN) has begun the regulatory process to seek early commercialization approval for its lead drug candidate, PrimeC, in Canada under Health Canada’s Notice of Compliance with Conditions (NOC/c) policy. This follows positive Phase 2b trial results, where PrimeC demonstrated a 36% reduction in ALS disease progression and a 43% improvement in survival rates. NeuroSense plans to pursue regulatory approvals in additional countries to expedite access to treatment for ALS patients.

About NeuroSense

NeuroSense Therapeutics, Ltd. is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. NeuroSense believes that these diseases, which include amyotrophic lateral sclerosis (ALS), Alzheimer’s disease and Parkinson’s disease, among others, represent one of the most significant unmet medical needs of our time, with limited effective therapeutic options available for patients to date. Due to the complexity of neurodegenerative diseases and based on strong scientific research on a large panel of related biomarkers, NeuroSense’s strategy is to develop combined therapies targeting multiple pathways associated with these diseases.